Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 23, Pages 15440
Publisher
MDPI AG
Online
2022-12-07
DOI
10.3390/ijms232315440
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Xin Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system
- (2022) Chang Hoon Ji et al. Nature Communications
- Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
- (2022) Pallavi M. Gosavi et al. ACS Central Science
- Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
- (2022) Alberto Juan et al. Frontiers in Cell and Developmental Biology
- Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
- (2022) Richard A Furie et al. Lupus Science & Medicine
- Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic
- (2022) Ulrike Tontsch-Grunt et al. BRITISH JOURNAL OF CANCER
- Absorption, distribution, metabolism, and excretion of FDA-approved antisense oligonucleotide drugs
- (2022) Julia M Migliorati et al. DRUG METABOLISM AND DISPOSITION
- Targeted protein degradation and drug discovery
- (2022) Mikihiko Naito JOURNAL OF BIOCHEMISTRY
- Proteolysis-targeting chimeras (PROTACs) in cancer therapy
- (2022) Xinyi Li et al. Molecular Cancer
- Deubiquitinase-targeting chimeras for targeted protein stabilization
- (2022) Nathaniel J. Henning et al. Nature Chemical Biology
- BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph + chronic myeloid leukemia
- (2022) Barbara Peter et al. AMERICAN JOURNAL OF HEMATOLOGY
- PROTACs for BRDs proteins in cancer therapy: a review
- (2022) Chao Wang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- (2022) Alessandra Salerno et al. JOURNAL OF MEDICINAL CHEMISTRY
- Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
- (2022) Jing Gao et al. Nature Communications
- BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
- (2022) Ellen Weisberg et al. Blood Cancer Journal
- The mechanism of action and clinical value of PROTACs: A graphical review
- (2022) Harriet Graham CELLULAR SIGNALLING
- Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
- (2022) Lin Zhang et al. Molecular Therapy-Nucleic Acids
- The Rise of Molecular Glues
- (2021) Stuart L. Schreiber CELL
- Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
- (2021) Adam D. Cotton et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes
- (2021) Da Han et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
- (2021) Peter S. Dragovich et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
- (2021) Peter S. Dragovich et al. JOURNAL OF MEDICINAL CHEMISTRY
- CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia
- (2021) Joshua D. Hansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
- (2021) Max Jan et al. Nature Reviews Clinical Oncology
- Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
- (2021) Ryan Kolb et al. Nature Communications
- Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
- (2021) Yaxian Zhou et al. ACS Central Science
- Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy
- (2021) Zonghui Ma et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Cancer statistics for the year 2020: An overview
- (2021) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer Selective Target Degradation by Folate-Caged PROTACs
- (2021) Jing Liu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Therapeutic targeting of RNA-binding protein by RNA-PROTAC
- (2021) Xinyi Li et al. MOLECULAR THERAPY
- Discovery and resistance mechanism of a selective CDK12 degrader
- (2021) Baishan Jiang et al. Nature Chemical Biology
- LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
- (2021) Green Ahn et al. Nature Chemical Biology
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
- (2021) Shipeng He et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer
- (2021) Daniel Westaby et al. Annual Review of Pharmacology and Toxicology
- In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
- (2021) Yubo Wang et al. BIOORGANIC CHEMISTRY
- Degradation of lipid droplets by chimeric autophagy-tethering compounds
- (2021) Yuhua Fu et al. CELL RESEARCH
- Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1
- (2021) So Ra Choi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Protein degradation technology: a strategic paradigm shift in drug discovery
- (2021) Haobin Li et al. Journal of Hematology & Oncology
- Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators
- (2021) Gisele Nishiguchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of a “Bump-and-Hole” Bromodomain-Based Degradation Tag
- (2021) Radosław P. Nowak et al. JOURNAL OF MEDICINAL CHEMISTRY
- TF-PROTACs Enable Targeted Degradation of Transcription Factors
- (2021) Jing Liu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Bifunctional small molecules that mediate the degradation of extracellular proteins
- (2021) David F. Caianiello et al. Nature Chemical Biology
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- (2021) Jingwei Shao et al. Advanced Science
- E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
- (2021) Aleša Bricelj et al. Frontiers in Chemistry
- Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
- (2021) Jaeki Min et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma
- (2021) Jesus Berdeja et al. BLOOD
- CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
- (2021) Paul G. Richardson et al. BLOOD
- Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor
- (2021) Rong Hu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
- (2021) Heng Zhang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeting selective autophagy by AUTAC degraders
- (2020) Daiki Takahashi et al. Autophagy
- Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
- (2020) Thomas L. Gonzalez et al. BREAST CANCER RESEARCH AND TREATMENT
- Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
- (2020) Olivier Mir et al. EUROPEAN JOURNAL OF CANCER
- Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2020) Joshua D. Hansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer
- (2020) Matthew G. Costales et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PHOTACs enable optical control of protein degradation
- (2020) Martin Reynders et al. Science Advances
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras
- (2020) Yingming Wang et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders
- (2020) Benjamin R. Bellenie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small molecules, big impact: 20 years of targeted therapy in oncology
- (2020) Philippe L Bedard et al. LANCET
- PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
- (2020) Sajid Khan et al. ONCOGENE
- Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative
- (2020) Jian Zhang et al. BIOORGANIC CHEMISTRY
- Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
- (2020) Binbin Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
- (2020) Iris Z. Uras et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
- (2020) Yonghan He et al. Journal of Hematology & Oncology
- Phosphorylation-Inducing Chimeric Small Molecules
- (2020) Sachini U. Siriwardena et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Lysosome-targeting chimaeras for degradation of extracellular proteins
- (2020) Steven M. Banik et al. NATURE
- The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
- (2020) Mikołaj Słabicki et al. NATURE
- Rational discovery of molecular glue degraders via scalable chemical profiling
- (2020) Cristina Mayor-Ruiz et al. Nature Chemical Biology
- Advances in oligonucleotide drug delivery
- (2020) Thomas C. Roberts et al. NATURE REVIEWS DRUG DISCOVERY
- Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics
- (2020) Ainsley Mike Antao et al. Cancers
- Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library
- (2020) Chelsea E. Powell et al. ACS Chemical Biology
- ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis
- (2020) Lina Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
- (2020) Malaka Ameratunga et al. BRITISH JOURNAL OF CANCER
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
- (2020) Mingming Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Management of ER positive metastatic breast cancer
- (2020) Nicholas P. McAndrew et al. SEMINARS IN ONCOLOGY
- PhotoPROTACs: A Novel Biotechnology for Cancer Treatment
- (2020) Zhi-wei Wang et al. TRENDS IN CELL BIOLOGY
- Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules
- (2020) Behnam Nabet et al. Nature Communications
- Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders
- (2020) Hafeez S. Haniff et al. ACS Central Science
- An IMiD-induced SALL4 degron system for selective degradation of target proteins
- (2020) Satoshi Yamanaka et al. Communications Biology
- RNA‐PROTACs: Degraders of RNA‐Binding Proteins
- (2020) Alice Ghidini et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Small-molecule-induced polymerization triggers degradation of BCL6
- (2020) Mikołaj Słabicki et al. NATURE
- Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
- (2020) Xinrui Yang et al. Targeted Oncology
- Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
- (2020) Shipeng He et al. Acta Pharmaceutica Sinica B
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
- (2019) Kyle R. Simonetta et al. Nature Communications
- Peptidic degron for IMiD-induced degradation of heterologous proteins
- (2019) Vidyasagar Koduri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Light-triggered release of photocaged therapeutics - Where are we now?
- (2019) Joana M. Silva et al. JOURNAL OF CONTROLLED RELEASE
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid and Reversible Knockdown of Endogenously Tagged Endosomal Proteins via an Optimized HaloPROTAC Degrader
- (2019) Hannah Tovell et al. ACS Chemical Biology
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation
- (2019) Hong Chen et al. BIOORGANIC CHEMISTRY
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
- (2019) Hannah Tovell et al. ACS Chemical Biology
- Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
- (2019) Patrick Pfaff et al. ACS Central Science
- Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
- (2019) Thomas H. Pillow et al. ChemMedChem
- Therapeutic applications of AS1411 aptamer, an update review
- (2019) Rezvan Yazdian-Robati et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
- (2019) Zhaoyang Li et al. NATURE
- Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
- (2019) Tyler B. Faust et al. Nature Chemical Biology
- Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820
- (2019) Xinlin Du et al. STRUCTURE
- Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
- (2019) Peter S. Dragovich et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study
- (2019) Sayumi Yamazoe et al. JOURNAL OF MEDICINAL CHEMISTRY
- AUTACs: Cargo-Specific Degraders Using Selective Autophagy
- (2019) Daiki Takahashi et al. MOLECULAR CELL
- Discovery of a first-in-class EZH2 selective degrader
- (2019) Anqi Ma et al. Nature Chemical Biology
- Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
- (2019) Dirksen E. Bussiere et al. Nature Chemical Biology
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- In Vivo Photopharmacology
- (2018) Katharina Hüll et al. CHEMICAL REVIEWS
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecule Targeted Recruitment of a Nuclease to RNA
- (2018) Matthew G. Costales et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The dTAG system for immediate and target-specific protein degradation
- (2018) Behnam Nabet et al. Nature Chemical Biology
- Homo-PROTACs for the Chemical Knockdown of Cereblon
- (2018) Christian Steinebach et al. ACS Chemical Biology
- Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
- (2018) Katherine A Donovan et al. eLife
- HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
- (2018) Huanbin Wang et al. Nature Chemical Biology
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
- (2018) Nobumichi Ohoka et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
- (2017) Andrew J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- How Big Is Too Big for Cell Permeability?
- (2017) Pär Matsson et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- Waste disposal—An attractive strategy for cancer therapy
- (2017) Jemilat Salami et al. SCIENCE
- Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
- (2017) Chiara Maniaci et al. Nature Communications
- Emerging Targets in Photopharmacology
- (2016) Michael M. Lerch et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Dysregulation of mRNA Localization and Translation in Genetic Disease
- (2016) Eric T. Wang et al. JOURNAL OF NEUROSCIENCE
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Aptamers as targeted therapeutics: current potential and challenges
- (2016) Jiehua Zhou et al. NATURE REVIEWS DRUG DISCOVERY
- Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
- (2016) Honorine Lebraud et al. ACS Central Science
- Analysis of nanoparticle delivery to tumours
- (2016) Stefan Wilhelm et al. Nature Reviews Materials
- HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
- (2015) Dennis L. Buckley et al. ACS Chemical Biology
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
- (2015) Jeffrey L. Gustafson et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Proteasome inhibitors
- (2015) Beverly A. Teicher et al. BIOCHEMICAL PHARMACOLOGY
- CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
- (2015) P. R. Hagner et al. BLOOD
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC)
- (2015) Geoffrey I. Shapiro et al. MOLECULAR CANCER THERAPEUTICS
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia
- (2014) Yaping Zhang et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Pharmacological targeting of the pseudokinase Her3
- (2014) Ting Xie et al. Nature Chemical Biology
- Ubiquitination in disease pathogenesis and treatment
- (2014) Doris Popovic et al. NATURE MEDICINE
- A census of human RNA-binding proteins
- (2014) Stefanie Gerstberger et al. NATURE REVIEWS GENETICS
- Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
- (2013) Camelia Iancu-Rubin et al. EXPERIMENTAL HEMATOLOGY
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
- (2013) Jonathan E. Rosenberg et al. INVESTIGATIONAL NEW DRUGS
- Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
- (2013) Lihua E. Budde et al. PLoS One
- Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs
- (2013) J. Hines et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Ubiquitin Code
- (2012) David Komander et al. Annual Review of Biochemistry
- Identification of Hydrophobic Tags for the Degradation of Stabilized Proteins
- (2012) Hyun Seop Tae et al. CHEMBIOCHEM
- The Development and Application of Optogenetics
- (2011) Lief Fenno et al. Annual Review of Neuroscience
- Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?
- (2011) Shankar Balasubramanian et al. NATURE REVIEWS DRUG DISCOVERY
- Two-Headed PROTAC: An Effective New Tool for Targeted Protein Degradation
- (2010) Kedra Cyrus et al. CHEMBIOCHEM
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- An auxin-based degron system for the rapid depletion of proteins in nonplant cells
- (2009) Kohei Nishimura et al. NATURE METHODS
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More